<p>Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the substantia nigra, leading to debilitating motor and non-motor symptoms. Current pharmacotherapies, including oral levodopa and dopamine agonists, are limited by poor bioavailability, high first-pass metabolism, fluctuating plasma drug levels, and frequent dosing, ultimately resulting in reduced therapeutic efficacy and patient compliance. These limitations have driven increasing interest in alternative drug delivery strategies capable of providing sustained and patient-friendly therapeutic administration. Microneedle (MN)-based transdermal drug delivery systems have emerged as a promising, minimally invasive alternative to address these challenges. MNs enable painless skin penetration, enhanced dermal permeability and sustained drug release. Fabrication methods such as photolithography, micromolding, and 3D printing allow precise control over MN geometry, insertion depth, and mechanical integrity, which holds particular promise for managing the dynamic symptom fluctuations characteristic of Parkinson’s disease. Additionally, the integration of nanocarriers and smart biosensing platforms has further expanded the potential of MN systems for controlled, targeted, and personalized therapy. In the context of Parkinson’s disease, MN-based transdermal systems represent a promising strategy to achieve stable dopaminergic stimulation, improve patient adherence, and enable self-administration. Furthermore, the integration of MN platforms with wearable biosensing technologies offers opportunities for real-time monitoring and personalized therapy, aligning with the growing emphasis on precision medicine. The review provides the clinical potential of MN technologies and represents a paradigm shift in PD therapy, offering a next-generation solution for effective, sustained, and patient-centric drug delivery.</p> Graphical Abstract <p></p>